Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum- β-lactamase-producing Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4899-4901

  Guet Revillet, H ^a,b   Emirian, A ^c,d   Groh, M ^b   Nebbad Lechani, B ^c   Weiss, E ^b   Join Lambert, O ^a,b   Bille, E ^a,b   Jullien, V ^e,f   Zahar, J R ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFOXITIN;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PYELONEPHRITIS; STATISTICAL MODEL; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CEFOXITIN; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PYELONEPHRITIS; URINARY TRACT INFECTIONS;

EID: 84905363996     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02509-14     Document Type: Article

References (18)

1. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, Lewis JS, Howard WJ, Johnson LE, Polsky B, Jorgensen JH, Richter SS, Shutt KA, Paterson DL. 2013. Community-associated extendedspectrum beta-lactamase- producing Escherichia coli infection in the United States. Clin. Infect. Dis. 56:641-648. http://dx.doi.org/10.1093/cid/cis942.
2. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
3. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686. http://dx.doi.org/10.1128/ CMR.18.4.657-686.2005.
4. Prinapori R, Guinaud J, Khalil A, Lecuyer H, Gendrel D, Lortholary O, Nassif X, Viscoli C, Zahar JR. 2013. Risk associated with a systematic search of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Am. J. Infect. Contro. 41:259-260. http://dx.doi.org/10.1016/j.ajic.2012.03.035.
5. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
6. Boyer M, Bignon A, Dessein R, Faure K, Guery B, Kipnis E. 2012. Cefoxitin and ESBL. Med. Mal. Infect. 42:126-128. http://dx.doi.org/10.1016/j.medmal. 2012.01.004.
7. Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B. 2012. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum beta-lactamase. Antimicrob. Agents Chemother. 56:1376-1381. http://dx.doi.org/10.1128/AAC.06233-11.
8. European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST, Basel, Switzerland. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/ Breakpoint-tables/Breakpoint-table-v-2.0-120221.pdf.
9. European Committee on Antimicrobial Susceptibility Testing. 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. EUCAST, Basel, Switzerland. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Resistance- mechanisms/EUCAST-detection-of-resistance-mechanisms-v1.0-20131211.pdf.
10. Comité de l'Antibiogramme de la Société Française de Microbiologie. 2012. Recommandations 2012. Société Française de Microbiologie, Paris, France. http://www.sfm-microbiologie.org/.
11. Isla A, Troconiz IF, de Tejada IL, Vazquez S, Canut A, Lopez JM, Solinis MA, Rodriguez Gascon A. 2012. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur. J. Clin. Pharmacol. 68:735-745. http://dx.doi.org/10.1007/s00228-011-1206-1.
12. Goldstein EJ, Citron DM, Cherubin CE. 1991. Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillinderived components of these combinations. Antimicrob. Agents Chemother. 35:560-566. http://dx.doi.org/10.1128/AAC.35.3.560.
13. Fournier D, Chirouze C, Leroy J, Cholley P, Talon D, Plesiat P, Bertrand X. 2013. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med. Mal. Infect. 43:62-66. http://dx.doi.org/10.1016/j.medmal.2013. 01.006.
14. Bradford PA. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. http://dx.doi.org/10.1128/CMR.14.4. 933-951.2001.
15. Pangon B, Bizet C, Bure A, Pichon F, Philippon A, Regnier B, Gutmann L. 1989. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J. Infect. Dis. 159:1005-1006. http://dx.doi.org/10.1093/infdis/159.5.1005.
16. Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. 1996. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expandedspectrum- cephalosporins. Antimicrob. Agents Chemother. 40:342-348.
17. Ananthan S, Subha A. 2005. Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and Escherichia coli. Indian J. Med. Microbiol. 23:20-23. http://dx.doi.org/10.4103/0255-0857.13867.
18. Palasubramaniam S, Muniandy S, Navaratnam P. 2009. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia. J. Microbiol. Immunol. Infect. 42:129-133.